Basic Information
| LncRNA/CircRNA Name | PCAT19 |
| Synonyms | NA |
| Region | GRCh38_19:41454169-41500649 |
| Ensemble | ENSG00000267107 |
| Refseq | NR_040109 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, luciferase reporter assay |
| Sample | cell lines |
| Expression Pattern | NA |
| Function Description | The risk variant is associated with decreased and increased levels of PCAT19-short and PCAT19-long, respectively. Mechanistically, the risk SNP region is bifunctional with both promoter and enhancer activity. PCAT19-Long Drives PCa Cell Proliferation and Progression In Vitro and In Vivo. Consistent with previous studies, patients with homozygous risk allele genotype G showed significantly shorter biochemical recurrence-free survival compared to patients with the non-risk allele genotype A (p = 0.032), suggesting a role for the risk SNP in disease progression after local therapy. PCAT19-long regulates cell proliferation, tumor growth, and metastasis. |
| Pubmed ID | 30033362 |
| Year | 2018 |
| Title | Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer Through lncRNA PCAT19. |
External Links
| Links for PCAT19 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |